Amphetamine abuse has severe health consequences. Persistent deficits in CNS function, altered cognition, and comorbid psychiatric conditions are suspected outcomes of long-term amphetamine abuse. The immense costs (medical, legal, societal) associated with any drug of abuse are compounded in the case of methamphetamine (METH) because it causes damage to the nervous system. Research in this project is translational in thrust, and will extend and capitalize on progress made in the study of METH-induced neurotoxicity during the previous funding period. Cellular stress caused by reactive oxygen/nitrogen species has been implicated in METH-induced neurotoxicity, but neither the specific reactant nor its cellular source has been identified. The long-term goal of this proposal is to increase understanding of the biochemical and cellular processes that mediate METH neurotoxicity, with a focus on microglia. Activated microglia produce numerous reactants that cause damage to neuronal tissue. On the other hand, pharmacological stimulation of selected microglial receptors can exert neuroprotective effects by preventing their activation. Therefore, the following specific aims will test the hypotheses that METH-induced microglial activation is a critical element of its neurotoxic cascade, and targeting of receptors on microglia that prevent or reduce their activation will protect against METH neurotoxicity: 1) determine the pharmacological and neurochemical features of METH-induced microglial activation with emphasis on the role of dopamine and its quinone;2) assess the functional consequences of microglial activation on METH-induced toxicity in cell culture and in vivo model systems- microglial activation will be provoked by the neurotoxic HIV Tat protein (and other activators) to enhance METH neurotoxicity, and neuroprotective receptors on microglia will be targeted by caffeine (adenosine) and estrogen (ERa) to protect against drug-induced neurotoxicity;and 3) delineate the mechanisms by which microglial activation alters the function of critical proteins (i.e., dopamine transporter and tyrosine hydroxylase) targeted for damage by METH. Completion of these specific aims will contribute to an increased understanding of the neurotoxicity associated with METH. The results of these studies will also have direct translational application to clinical settings where the comorbid consequences of drug abuse are being manifested with increased frequency. Research in this proposal is especially relevant to AIDS- related neuropathology, Parkinson's disease, and other neurodegenerative conditions in which microglial activation contributes to CNS damage.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA010756-12
Application #
7846166
Study Section
Neurobiology of Motivated Behavior Study Section (NMB)
Program Officer
Frankenheim, Jerry
Project Start
1997-09-29
Project End
2012-05-31
Budget Start
2010-06-01
Budget End
2011-05-31
Support Year
12
Fiscal Year
2010
Total Cost
$325,458
Indirect Cost
Name
Wayne State University
Department
Psychiatry
Type
Schools of Medicine
DUNS #
001962224
City
Detroit
State
MI
Country
United States
Zip Code
48202
Angoa-Pérez, Mariana; Kane, Michael J; Herrera-Mundo, Nieves et al. (2014) Effects of combined treatment with mephedrone and methamphetamine or 3,4-methylenedioxymethamphetamine on serotonin nerve endings of the hippocampus. Life Sci 97:31-6
Angoa-Pérez, Mariana; Kane, Michael J; Briggs, Denise I et al. (2013) Mephedrone does not damage dopamine nerve endings of the striatum, but enhances the neurotoxicity of methamphetamine, amphetamine, and MDMA. J Neurochem 125:102-10
Angoa-Pérez, Mariana; Kane, Michael J; Briggs, Denise I et al. (2012) Genetic depletion of brain 5HT reveals a common molecular pathway mediating compulsivity and impulsivity. J Neurochem 121:974-84
Angoa-Pérez, Mariana; Kane, Michael J; Francescutti, Dina M et al. (2012) Mephedrone, an abused psychoactive component of 'bath salts' and methamphetamine congener, does not cause neurotoxicity to dopamine nerve endings of the striatum. J Neurochem 120:1097-107
Kane, Michael J; Angoa-Pérez, Mariana; Briggs, Denise I et al. (2012) A mouse model of human repetitive mild traumatic brain injury. J Neurosci Methods 203:41-9
Kuhn, Donald M; Angoa-Pérez, Mariana; Thomas, David M (2011) Nucleus accumbens invulnerability to methamphetamine neurotoxicity. ILAR J 52:352-65
Kuhn, Donald M; Sykes, Catherine E; Geddes, Timothy J et al. (2011) Tryptophan hydroxylase 2 aggregates through disulfide cross-linking upon oxidation: possible link to serotonin deficits and non-motor symptoms in Parkinson's disease. J Neurochem 116:426-37
Thomas, David M; Angoa Perez, Mariana; Francescutti-Verbeem, Dina M et al. (2010) The role of endogenous serotonin in methamphetamine-induced neurotoxicity to dopamine nerve endings of the striatum. J Neurochem 115:595-605
Angoa-Perez, Mariana; Kreipke, Christian W; Thomas, David M et al. (2010) Soman increases neuronal COX-2 levels: possible link between seizures and protracted neuronal damage. Neurotoxicology 31:738-46
Thomas, David M; Francescutti-Verbeem, Dina M; Kuhn, Donald M (2009) Increases in cytoplasmic dopamine compromise the normal resistance of the nucleus accumbens to methamphetamine neurotoxicity. J Neurochem 109:1745-55

Showing the most recent 10 out of 36 publications